Traumatic Retinal Detachment in Patients with Self-Injurious Behavior: An International Multicenter Study.


Journal

Ophthalmology. Retina
ISSN: 2468-6530
Titre abrégé: Ophthalmol Retina
Pays: United States
ID NLM: 101695048

Informations de publication

Date de publication:
08 2021
Historique:
received: 25 08 2020
revised: 05 11 2020
accepted: 09 11 2020
pubmed: 26 11 2020
medline: 11 1 2022
entrez: 25 11 2020
Statut: ppublish

Résumé

To describe the clinical characteristics, surgical outcomes, and management recommendations in patients with traumatic rhegmatogenous retinal detachment (RRD) resulting from self-injurious behavior (SIB). International, multicenter, retrospective, interventional case series. Patients with SIB from 23 centers with RRD in at least 1 eye. Clinical histories, preoperative assessment, surgical details, postoperative management, behavioral intervention, and follow-up examination findings were reviewed. The rate of single-surgery anatomic success (SSAS) was the primary outcome. Other outcomes included new RRD in formerly attached eyes, final retinal reattachment, and final visual acuity. One hundred seven eyes with RRDs were included from 78 patients. Fifty-four percent of patients had bilateral RRD or phthisis bulbi in the fellow eye at final follow-up. The most common systemic diagnoses were autism spectrum disorder (35.9%) and trisomy 21 (21.8%) and the most common behavior was face hitting (74.4%). The average follow-up time was 3.3 ± 2.8 years, and surgical outcomes for operable eyes were restricted to patients with at least 3 months of follow-up (81 eyes). Primary initial surgeries were vitrectomy alone (33.3%), primary scleral buckle (SB; 26.9%), and vitrectomy with SB (39.7%), and 5 prophylactic SBs were placed. Twenty-three eyes (21.5%) with RRDs were inoperable. The SSAS was 23.1% without tamponade (37.2% if including silicone oil), and final reattachment was attained in 80% (36.3% without silicone oil tamponade). Funnel-configured RRD (P = 0.006) and the presence of grade C proliferative vitreoretinopathy (P = 0.002) correlated with re-detachment. The use of an SB predicted the final attachment rate during the initial surgery (P = 0.005) or at any surgery (P = 0.008. These associations held if restricting to 64 patients with ≥12 months followup. Anatomic reattachment correlated with better visual acuity (P < 0.001). RRD resulting from SIB poses therapeutic challenges because of limited patient cooperation, bilateral involvement, chronicity, and ongoing trauma in vulnerable and neglected patients. The surgical success rates were some of the lowest in the modern retinal detachment literature. The use of an SB may result in better outcomes, and visual function can be restored in some patients.

Identifiants

pubmed: 33238225
pii: S2468-6530(20)30463-2
doi: 10.1016/j.oret.2020.11.012
pii:
doi:

Substances chimiques

Silicone Oils 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

805-814

Informations de copyright

Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Auteurs

Elizabeth J Rossin (EJ)

Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Irena Tsui (I)

Stein Eye Institute, Department of Ophthalmology, University of California, Los Angeles, Los Angeles, California.

Sui Chien Wong (SC)

Department of Ophthalmology, Great Ormond Street Hospital and NIHR Biomedical Research Centre, London, United Kingdom; National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital, London, United Kingdom; Department of Ophthalmology, Royal Free Hospital, London, United Kingdom.

Kirk K Hou (KK)

Stein Eye Institute, Department of Ophthalmology, University of California, Los Angeles, Los Angeles, California.

Supalert Prakhunhungsit (S)

Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida.

Michael P Blair (MP)

Retina Consultants, Ltd, Des Plaines, Illinois.

Michael J Shapiro (MJ)

Retina Consultants, Ltd, Des Plaines, Illinois.

Lisa Leishman (L)

Retina Consultants, Ltd, Des Plaines, Illinois.

Aaron Nagiel (A)

The Vision Center, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, California; USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Jacob A Lifton (JA)

The Vision Center, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, California; USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Polly Quiram (P)

VitreoRetinal Surgery, PA, Minneapolis, Minnesota.

Alexander L Ringeisen (AL)

VitreoRetinal Surgery, PA, Minneapolis, Minnesota.

Robert H Henderson (RH)

Department of Ophthalmology, Great Ormond Street Hospital and NIHR Biomedical Research Centre, London, United Kingdom.

Natalia Arruti (N)

Department of Ophthalmology, Great Ormond Street Hospital and NIHR Biomedical Research Centre, London, United Kingdom.

Dominic M Buzzacco (DM)

Midwest Retina, Inc, Dublin, Ohio.

Shunji Kusaka (S)

Department of Ophthalmology, Kindai University Faculty of Medicine, Osaka, Japan.

Philip J Ferrone (PJ)

Long Island Vitreoretinal Consultants, Great Neck, New York.

Peter J Belin (PJ)

Long Island Vitreoretinal Consultants, Great Neck, New York.

Emmanuel Chang (E)

Retina and Vitreous of Texas, Houston, Texas.

Jean-Pierre Hubschman (JP)

Stein Eye Institute, Department of Ophthalmology, University of California, Los Angeles, Los Angeles, California.

Timothy G Murray (TG)

Miami Ocular Oncology and Retina, Miami, Florida.

Ella H Leung (EH)

Cullen Eye Institute, Baylor College of Medicine, Houston, Texas.

Wei-Chi Wu (WC)

Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Karl R Olsen (KR)

Retina Vitreous Consultants, Monroeville, Pennsylvania.

C Armitage Harper (CA)

Austin Retina Associates, University of Texas-Austin, University of Texas-San Antonio, Austin and San Antonio, Texas.

Safa Rahmani (S)

Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Jessica Goldstein (J)

Austin Retina Associates, University of Texas-Austin, University of Texas-San Antonio, Austin and San Antonio, Texas.

Thomas Lee (T)

The Vision Center, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, California; USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Eric Nudleman (E)

Department of Ophthalmology, Shiley Eye Institute, University of California, San Diego, San Diego, California.

Linda A Cernichiaro-Espinosa (LA)

Asociacion para Evitar la Ceguera en México, Mexico City, Mexico.

Jay Chhablani (J)

Smt. Kanuri Santhamma Centre for Vitreo-Retinal Diseases, L. V. Prasad Eye Institute, Hyderabad, India; Department of Ophthalmology, UPMC Eye Center, University of Pittsburgh, Pittsburgh, Pennsylvania.

Audina M Berrocal (AM)

Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida.

Yoshihiro Yonekawa (Y)

Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: yyonekawa@midatlanticretina.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH